Click any tag below to further narrow down your results
Links
Researchers led by Elizabeth Adamala built SpudCell from nonliving ingredients, and it can grow, copy its DNA, and divide. The article asks what people should do with a synthetic cell that comes this close to life.
- SpudCell can grow, copy its DNA, divide in two, and restart its cell cycle, all from ingredients that were not alive.
- It was unveiled in July, and some experts called it the closest science has come to making life from scratch.
- The open question the piece focuses on is how society should handle and regulate a cell this close to living.
Copenhagen startup BioinvestGPT runs virtual versions of drug trials with its AI models, and it says its forecasts were right in five of six cases so far. The companies behind these tools hope that testing drugs in simulation first will help more of them succeed in real human studies.
- BioinvestGPT shared its predictions for several high-profile drug trials with Reuters in July, before those results were public.
- The firm has been correct in five of six of those forecasts so far, a small sample that still needs more track record to judge.
- The pitch is that better virtual trials could cut the failure rate of expensive human studies.
Enveda, which uses AI to find drug candidates in plants and microbes rather than synthesizing them, just doubled its valuation to $2 billion with a Series E round. The startup has moved beyond discovery into human trials—testing drugs for skin conditions and weight loss maintenance.
- Enveda raised $311 million at a $2 billion valuation, doubling its value in 12 months
- The company has multiple drugs in clinical trials, including treatments for severe skin conditions and post-GLP-1 weight loss
- No AI-discovered drug has received FDA approval yet, but Enveda is part of a wave of biotech companies pushing candidates into human testing
Insilico Medicine used artificial intelligence to develop rentosertib, a drug for chronic lung disease, and early trial data suggests it may also reduce biological markers of aging. The findings come with major caveats: the sample size was small, the drug hasn't been tested in healthy people, and the "aging clocks" used to measure results are scientifically debated.
- Rentosertib reduced biological aging markers across six different AI-based "aging clocks" in a clinical trial, according to results published in Nature Biotechnology.
- The drug was originally developed for idiopathic pulmonary fibrosis (IPF) and has only been tested in sick patients, not healthy ones, so anti-aging claims remain speculative.
- The study has significant limitations: small sample size, unproven reliability of aging clock measurements, and the drug is still years away from regulatory approval even for its primary lung disease indication.
10x Science built a platform that uses chemistry-based algorithms and AI agents to interpret complex mass spectrometry data, speeding up protein characterization for drug development. Backed by a $4.8 million seed round, it helps biotechs and pharma quickly validate AI-generated treatment candidates. The startup plans to refine its models and expand offerings by integrating broader cellular data.
- 10x Science raised a $4.8M seed round led by Initialized Capital to build AI that interprets mass spectrometry data for drug candidate validation, addressing the bottleneck created by AI protein-folding tools flooding pipelines with candidates.
- Its platform is fully traceable rather than a black box, which matters for regulatory compliance—unlike prior tools that over-promised or failed on complex molecules.
- Early users like Rilas Technologies report it shaves weeks off workflows, with the AI accurately identifying proteins by name and pulling sequences from public databases.
- Long-term plan is to layer cellular data on top of protein structure to create "molecular intelligence," positioning it as a potential go-to analytics engine for AI-driven drug development.
Andreessen Horowitz has successfully raised over $15 billion to invest in various sectors, including AI, crypto, and health, aiming to ensure America's technological leadership. The firm emphasizes the importance of providing opportunities for individuals to contribute to society while addressing the competitive landscape against China.
- a16z raised over $15B to invest across AI, crypto, and health/biotech
- The firm frames its mission around maintaining American technological leadership, particularly against China
- The pitch emphasizes giving individuals the resources and opportunity to build and contribute to society
Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.
- Boltz raised a $28 million seed round and partnered with Pfizer to advance open-source drug design models.
- Over 100,000 scientists are already using Boltz's tools, positioning it as a widely-adopted open-science alternative to closed AI drug discovery platforms.
- The core bet is that open-source, freely accessible AI models can accelerate biological research and drug development faster than proprietary approaches.